MAFLD – Latest consensus statement for assessment in primary care

28th September 2024, A/Prof Chee L Khoo

MALFD

Patients are often given tacit recommendations about lifestyle changes for MAFLD because it’s “just a little fat in the liver”. For those of us who have that few patients with those liver as well as non-liver complications, we will remember how horrible these patients fare moving forward. Yet, we can’t refer all our patients with fatty liver to the hepatologist.…

Diabetic retinopathy – a new paradigm change in management coming…

28th September 2024, A/Prof Chee L Khoo

diabetic retinopathy (DR)

Diabetic retinopathy (DR) is the leading cause of new cases of blindness in patients with diabetes mellitus. In 2020, more than 103 million individuals with diabetes mellitus worldwide were affected by diabetic retinopathy and it is expected that this number will increase to 160 million by 2045 (1). We are all familiar with the association between poor glycaemic control and diabetic retinopathy development and progression.…

HFpEF management – a second kid on the block has emerged

12th September 2024, A/Prof Chee L Khoo

finerenone

We explored the four pillars of treatment for patients with heart failure with reduced ejection fraction (HFrEF) a few years ago now. In patients with heart failure with preserved ejection fraction (HFpEF) however, the options are quite limited. SGLT2 inhibitors is the only class of agents that has been shown to reduce major adverse cardiovascular events (MACE).…

CKD – high protein intake or not?

12th September 2024, A/Prof Chee L Khoo

Protein

Inadequate protein intake in older adults may cause impairments of muscle mass and muscle function as well as impairment in immune function. Higher protein intake has been associated with increased muscle mass and strength, slower rate of bone loss, higher bone mineral density, lower risk of frailty, and improved cardiovascular function and recovery from illness (including wound healing) (1,2).…

VLCD – does it work? Is it safe?

30th August 2024, A/Prof Chee L Khoo

Up until GLP1RAs +/- GIPs were shown to be efficacious in assisting patients lose weight and keeping the weight off, long term sustainable weight loss was practically unachievable. Not everyone wants to or is able to afford bariatric surgery to assist in weight loss. Even then, the weight loss is usually not sustainable. International guidelines (including Australian) include medical nutritional therapy in the management of obesity.…

Hypertriglyceridaemia – is fenofibrate all we have?

24th August 2024, A/Prof Chee L Khoo

Last fortnight we looked at the effects of hypertriglyceridaemia (HTG) on atherosclerosis. We explored the source and metabolism of triglycerides (TG). We saw how important lipoprotein lipase was in regulating plasma TG. Triglyceride levels are closely related to plasma triglycerides rich lipoprotein (TRL) and TRL remnants. All three components penetrate through the endothelium into the subendothelial space where atherosclerotic inflammation occur.…

Plasma glucose – how accurate is the reading?

24th August 2024, A/Prof Chee L Khoo

glucose analysis

Plasma glucose levels is such a simple test that we take for granted its reliability. The glucose level is absolutely critical in many of our clinical management. It governs whether we diagnose someone with diabetes or not and that have many regulatory implications. We have discussed the diagnosis and management of gestational diabetes mellitus (GDM) and how it affects maternal and offspring outcomes and future risks to both.…

Does low salt really reduce BP and CVD?

More salt?

High salt intake is said to independently contribute to high blood pressure and ultimately, increase cardiovascular disease (CVD). There are also many other diseases that are similarly associated with high salt intake. How robust is the evidence though? As we ponder about the associations, we may or may not push the message of salt reduction as strongly as we should.…

Does salt reduction really reduce BP and CVD?

21st July 2024, A/Prof Chee L Khoo

Salt intake

I know this what we were all led to believe – high salt intake independently contributes to high blood pressure and ultimately, increases cardiovascular disease (CVD). Further, reducing salt intake will reduce blood pressure and thence, cardiovascular disease. We may sometimes wonder how strong the evidence for both statements is. As we ponder about the associations, we may or may not push the message of salt reduction as strongly as we should.…

Intravenous iron for iron deficiency – can you give too much?

13th July 2024, A/Prof Chee L Khoo

Iron infusion

Iron deficiency can occur in a number of scenarios. It can arise from blood loss (gastrointestinal, gynaecological), inadequate dietary sources or limited absorption in inflammatory conditions (e.g CKD, heart failure or diabetes). Oral iron supplements not only can have annoying GI side effects but absorption is poor under the best of conditions.…

SMuRF-less myocardial infarctions – what are they?

12th July 2024, A/Prof Chee L Khoo

Myocardial Infarction

We are always on the look out for the traditional cardiovascular risk factors – hypertension, diabetes, lipids and smoking to reduce the risk of adverse cardiovascular events. These are termed standard modifiable cardiovascular risk factors (SMuRFs). Unfortunately, there are a significant number of patients that present with acute coronary syndrome (ACS) who has none of the SMuRFs.…

The deadly exacerbations of COPD

30th June 2024, A/Prof Chee L Khoo

CVD in COPD

We are all aware of the exacerbations in patients with chronic obstructive pulmonary disease (COPD) especially when they are discharged from hospital back to primary care. We tend to forget that each time a patient with COPD have flare up or chest infection, that represent an exacerbation of COPD. Now, you may think it’s just a matter of semantics and coding but it’s more than that.…